ERBB2 and breast cancer: Zong et al. have also reported a higher rate of first-2-year relapse in patients with ER+/PR-/HER2– breast cancer when compared to those with ER+/PR+/HER2– tumor, suggesting that PR status could be adopted as a stable and reliable indicator of endocrine resistance in routine clinical practice (30).